Takeda Pharmaceutical Co. Limited (TKPYY.PK, TKPHF.PK) and its unit Millennium: The Takeda Oncology Company Sunday announced data from a meta-analysis of Velcade-based regimens compared to non-Velcade-based regimens as induction therapy prior to autologous stem cell transplant or ASCT in patients with previously untreated multiple myeloma or MM.
These data were reported in an oral presentation at the 14th International Myeloma Workshop held April 3-7, 2013 in Kyoto, Japan.
According to the company, the median progression-free survival or PFS was ''significantly higher with VELCADE-based induction therapy compared to non-VELCADE-based: 35.9 months compared to 28.6 percent respectively..., at a median follow up of 37 months'.'
The post transplant combined complete response or CR plus near-complete response or nCR rate, was 38 percent compared to 24 percent, odds ratio of 2.05. An odds ratio greater than 1 indicates the increased odds a patient will achieve an endpoint with one treatment over the odds of achieving that endpoint with a comparator-treatment.
In the meta-analysis Velcade-based induction treatment demonstrated a 23 percent overall survival benefit compared to non-Velcade-based induction treatment.
For comments and feedback: editorial@rttnews.com